Group items tagged

Childbirth is an emotional, intimate moment for new parents. Unfortunately, there are plenty of cases where, during the birth process, the newborn may suffer a physical injury. Parents need to know their rights to check their child's medical records if they suspect that medical malpractice caused the damage. In our following guide, we're sharing some top facts on birth injuries and what one can do when facing this complex scenario. THE MAIN CAUSES BEHIND BIRTH INJURIES No parent walks into the hospital during childbirth expecting the worst-case scenario. However, one of the primary ways families can reduce the chances of dealing with this complex situation is to plan with their attending medic and check for any obstetrical risk factors before birth. A difficult birth can happen because the baby weighs over 8 pounds or 4 kilograms, or labor has started before 37 weeks. Other common factors detected during these cases occur when the mother's pelvis doesn't have the ideal conditions for natural childbirth, maternal obesity is present, or labor has extended for more than 12 hours. However, if medical professionals cannot deal with these factors and make mistakes during the procedure, the chances of suffering any birth injury increase significantly.

Hundreds of children in England are set to benefit from a treatment for cystic fibrosis - Kaftrio, after the UK's Medicines and Healthcare products Regulatory Agency (MHRA) confirmed an extension to its licence. With the licence extension, more than 1,300 children in England with cystic fibrosis, aged six to 11, are newly eligible for this treatment, which improves lung function and improves overall quality of life of patients. Earlier, Kaftrio was only licensed for those aged 12 and above. British patients were the first in Europe to benefit from Kaftrio, when NHS England secured a landmark deal in June 2020. NHS chief executive Amanda Pritchard said: "Since NHS staff delivered one of the fastest rollouts of Kaftrio in the world just over a year ago, the lives of thousands of patients with cystic fibrosis have been transformed. "Innovative treatments like Kaftrio are life-changing for patients and their families, and that is why the NHS has done all it can since we secured the deal for Kaftrio to ensure patients benefit as soon as possible.

Even as the UK agrees deals for 14 million additional vaccine doses from Moderna and Pfizer, the Royal Pharmaceutical Society has renewed its calls for community pharmacies in England to play an increased role in delivering booster jabs for Covid-19. "Pharmacists and pharmacy teams across the health service in England have been crucial to the success of the flu and Covids-19 vaccination programmes from the outset," said Thorrun Govind, chair of the RPS in England, who has been making a case on national television for an increased role of the profession. She added: "They continue to go above and beyond to support patient care, engaging with local communities and helping to overcome vaccine hesitancy. "They've already done so much this year to look after patients in really difficult circumstances, but many will be ready to rise to the challenge of this new national effort."

The Pharmacists' Defence Association (PDA) is playing a vital role in helping pharmacists who are dealing with stress at the workplace. It launched its new awareness factsheet 'It's Time to Address Stress' last week. The factsheet looks at the causes and symptoms of stress in the workplace and provides advice on ways pharmacists can access support and improve working conditions. The association said that it recognises the well-being services offered by employers and specialist charities such as the PDA's charity partner Pharmacist Support play an important part in helping pharmacists who may be experiencing stress. However, the PDA is also committed to working with members to challenge employers to provide well workplaces and to help them to make real impact changes. This can be done by addressing the causes of stress and fulfilling their responsibilities to their employees. It added: "Under the management of Health and Safety at Work Regulations 1999, employers are required by law to protect employees from harm. Their legal obligations include identifying hazards and risks and implementing ways to reduce or eliminate them. The PDA's new factsheet highlights the importance of employers recognising the hazards causing stress as the health and safety issues they are."

Pharmaceutical giant AstraZeneca will acquire biotechnology company Neogene Therapeutics for up to $320 million, the London-listed drugmaker said on Tuesday (November 29) as it seeks to build its pipeline of cell-based cancer treatments. Though AstraZeneca's oncology portfolio accounted for more than a third of the company's revenue last year, it does not have an approved cell-based cancer therapy and is behind rivals such as Novartis and Gilead. "Neogene's leading (T-cell receptor) discovery capabilities and extensive manufacturing experience complement the cell therapy capability we have built over the last three years," said Susan Galbraith, AstraZeneca's executive vice president of oncology research. Cell-based treatments are a relatively new approach to treating cancer, most of which involve drawing the body's own immune cells and processing them in the lab to target and kill cancer cells. Neogene's approach goes one step further in that its experimental T-cell receptor therapies seek to target DNA mutations specific to tumours, not only certain proteins on the surface of cancer cells.

A pharmacy group operating in London and the surrounding areas has said it's cliched a financial deal worth £4.25 million with a major global bank to bolster its mergers and acquisitions activity. Osbon Pharmacy Group said on Monday (19 June) that it would use the multi-million-pound funding package from HSBC UK to also invest in bringing accessible and comprehensive medical services closer to the doorstep of Londoners and people of South East England. The family-run business said the new money will open new position which will include opportunities for pharmacists, pharmacy assistants, pharmacy technicians, dispensers, accounts clerks and delivery drivers, taking the company's total headcount to 185. The group, which currently has 26 pharmacies across London and South East England, was established in 2005. The company offers a range of medicine and prescription services as well as offering customary help and advice. It switched to banking with HSBC UK last year as part of a £6.9M refinance package, which saw the business acquire nine pharmacies and takes the total funding provided by HSBC UK to date to £11.1m.

Walgreens Boots Alliance on Tuesday (June 28) scrapped the plan to sell its UK high street pharmacy chain saying no third party was able to make an adequate offer due to the turmoil in global financial markets. Walgreens' move to call off the sale comes as private equity bidders Apollo Global and TDR faced headwinds in raising financing for the deal, as banks were wary of underwriting large chunks of the financing due to tough market conditions. Boots was initially valued at as much as £8bn with the auction process being led by Goldman Sachs. Global economic uncertainty and rising inflation have triggered a spike in interest rates as central banks have rushed to take action in the most widespread tightening of monetary policy for more than two decades, making deal financing costlier and harder to access. Walgreens had put its Boots UK business up for sale after announcing a strategic review in January as the second-largest US pharmacy chain renewed its focus on domestic healthcare. The company said the decision to retain Boots and No7 Beauty Company was also underpinned by their ongoing strong performance.

NHS England has secured a deal for 'Dexcom ONE Real Time-Continuous Glucose Monitoring' device which will help type 1 diabetes patients to keep track of their glucose levels at all times without having to scan or take a finger prick test. Once the patients receive their starter pack - which will include information on the product and usage, a sensor and transmitter - from the hospital or GP surgery, they can go to the community pharmacy for their repeat prescription. The wearable arm gadget sends information to a mobile app and allows diabetes patients to keep track of their glucose levels. "Traditionally, continuous glucose monitors are more expensive than their flash monitor counterparts - which record glucose levels by scanning a sensor - but thanks to the NHS agreeing on a new cost-effective deal with manufacturers DEXCOM, they will now be available for NHS patients on prescription at a similar price," said NHS. Dexcom ONE Real Time-Continuous Glucose Monitoring, uses a sensor no bigger than a bottle cap that attaches to the arm for up to 10 days and measures glucose levels from just under the skin. The wider rollout of the technology will help diabetes patients manage their condition better - reducing hospitalisations and associated diabetic illnesses which will ultimately ease pressure off the NHS. Karen Baxter, vice president, UK & Ireland, Benelux, France and Spain at Dexcom: "The addition of Dexcom ONE to the NHS England drug tariff is enormous progress towards improving the choice of diabetes tech, providing an alternative to burdensome finger pricks and scanning.

Following the UK government's new pay offer to NHS consultants, the Royal College of Nursing (RCN) wrote to the Health Secretary Victoria Atkins calling for fresh negotiations about nursing pay in England last week. However, the Department of Health and Social Care (DHSC) has rejected their demand, stating that there is no basis to reopen talks as the pay deal was accepted by the NHS Staff Council. In the previous pay deal, nurses were given a one-off payment between £1,655 and £3,789 for 2022/23, and a 5 per cent consolidated pay increase for the 2023/24 financial year. Nursingnotes quoted a DHSC spokesperson as saying: "We hugely value the hard work of NHS nurses and that is why we provided a 5 per cent pay rise. "We also provided two significant non-consolidated awards, which for nurses at the top of Band 5 was over £2,000, equivalent to an extra 6.1 per cent of their basic pay.

The tripartite negotiations to set the arrangements for the Community Pharmacy Contractual Framework (CPCF) in 2022/23 - Year 4 of the five-year CPCF deal - have now begun, the Pharmaceutical Services Negotiating Committee (PSNC) said. The discussions, beginning ahead of the start of the financial year, are taking place between the PSNC and the Department of Health and Social Care (DHSC) and the NHS England and NHS Improvement (NHSE&I). It will cover issues related to service, funding and other arrangements for pharmacies in 2022/23, in line with the five-year CPCF deal. The three entities will also discuss the progress made to date, which has been partly impacted by the Covid-19 pandemic, and the recent joint Annual Review process, where PSNC raised serious concerns around the available capacity within community pharmacy.

Amgen Inc on Monday agreed to buy Horizon Therapeutics Plc in a deal valued at $27.8 billion (£22.67bn), fortifying its rare diseases portfolio in the biggest buyout in the sector this year. The company will pay $116.50 in cash, a premium of nearly 20 per cent to the stock's last close, for each Horizon share. Horizon shares closed up 15 per cent on Monday at $112.36. They had climbed 23.5 per cent through Friday since the company disclosed in late November it was in preliminary talks with Amgen, Sanofi and Johnson & Johnson for potential offers. Amgen shares dipped less than 1 per cent to close at $276.78. Sanofi said Sunday it ended discussions with Horizon after concluding the transaction prices "do not meet our value criteria." J&J also said in early December that it had dropped its pursuit of the deal.

British drugmaker AstraZeneca says it's confident that its new version of COVID-19 antibody treatment could protect immunocompromised patients against all known virus variants. Laboratory studies show the antibody, called AZD3152, neutralises all known variants of COVID-19 and AstraZeneca has support from regulators to make the treatment available by the end of this year, the company's vaccines head Iskra Reic said on Tuesday (April 18). AstraZeneca plans, pending more positive data and regulatory approval, to make the antibody available by the end of 2023. These types of therapies are most needed for people with compromised immune systems, either because of underlying conditions or because they are undergoing immune suppressing treatments. They account for nearly 2% of the global population. AstraZeneca's AZD3152, it new COVID-19 antibody, was acquired through a $157 million deal last year with British biotech start-up RQ Bio. The British drugmaker will likely make future investments like its current partnerships with RQ Bio but did not have any deals to announce, said Reic, a long-time AstraZeneca executive who has led the company's vaccines and immune therapies unit since it was formed in late 2021, during the pandemic.

PBR Staff Writer Published 22 April 2014 Swiss pharmaceutical firm Novartis has entered into a definitive agreement to acquire the oncology unit of Britain's GlaxoSmithKline (GSK) for about $14.5bn and up to $1.5bn contingent on a development milestone. As part of the deal, Novartis would have opt-in rights to GSK's current and future oncology R&D pipeline.

Consumer goods giant Unilever signalled on Monday (January 17) it would pursue a deal for GlaxoSmithKline's consumer healthcare business, calling it a "strong strategic fit" after its £50 billion offer was refused. GSK confirmed on Saturday that it had rejected three approaches from the Dove-soap maker, adding it intended to stick to its own plan to spin off the business as a separate company later this year. "GSK Consumer Healthcare would be a strong strategic fit," Unilever said in a statement as it unveiled a strategy update in the wake of the weekend's takeover news. Unilever said it was "committed to accelerating the company's growth and repositioning the portfolio into higher growth categories. "As a result of the reporting of Unilever's interest in GSK Consumer Healthcare, we are today bringing forward a planned update, setting out the strategic direction that the company is pursuing," Unilever said.

Pharmaceutical companies AbbVie and Eli Lilly have withdrawn from Britain's voluntary medicines pricing agreement, an industry body said on Monday. Companies are increasingly arguing that it is no longer possible to justify the UK's "voluntary scheme" to global boardrooms and investors as repayment rates in 2023 have surged to 26.5 per cent of revenue, the Association of the British Pharmaceutical Industry (ABPI) said in a statement. "The current scheme has harmed innovation, with costs spiralling out of control, and the UK falling behind other major countries to be left as a global outlier," said Laura Steele, president and general manager for Eli Lilly's Northern Europe division. ABPI said it was seeking early talks with the government to set out a new future settlement. In December, the industry body had said the government raised the amount manufacturers of branded medicines within the voluntary scheme will be required to return to almost £3.3 billion in sales revenue from an earlier amount of £1.8 billion.

The Department of Health and Social Care (DHSC), NHS England and the Association of the British Pharmaceutical Industry (ABPI) have reached an agreement on the 2024 voluntary scheme for branded medicines pricing, access and growth (VPAG). The landmark deal will save the NHS £14 billion over 5 years in medicines costs, boost the nation's health, and support research investment. The new VPAG scheme, which will be a non-contractual voluntary agreement between DHSC and ABPI, will run for 5 years from 1 January 2024 until 31 December 2028. It will double the annual allowed growth of sales of branded medicines from two per cent per year in 2024 to four per cent per year by 2027.

The Pharmacists' Defence Association (PDA) is probing major concerns arising from Boots' communications to pharmacists regarding the company's recently announced pension arrangements. In November, Walgreens Boots Alliance (WBA), the parent company of Boots, transferred the Boots employees' pension scheme to the financial service provider Legal and General (L&G) in a £4.8 billion deal. Boots notified staff that terms allowing an unreduced pension from age 60 have ceased immediately, following its agreement with L&G. The PDA highlighted member concerns regarding Boots management's announcement that an unreduced pension from the age of 60 is a discretionary benefit and not guaranteed under the Boots Pension Scheme (BPS), contrary to some members' assumptions.

While Northern Irish business groups has welcomed the certainty a new EU-UK deal on post-Brexit trade rules for the region provided, the pharmaceutical industry too has expressed cautious optimism. In his speech on the Windsor Framework on Monday (February 28) Prime Minister Rishi Sunak said the agreement "delivers a landmark settlement on medicines". "From now on, drugs approved for use by the UK's medicines regulator will be automatically available in every pharmacy and hospital in Northern Ireland," he announced. The National Pharmacy Association's Northern Ireland manager Anne McAlister expressed a sense of cautious optimism. She said: "While the devil may yet be in the detail, the Windsor Framework would appear to be good news for pharmacies in Northern Ireland. It seems to address the main concerns we have expressed about medicines supplies to NI, but we want to examine the small print to ensure the new arrangements meet the needs of our members and the patients they serve.

Asbestos poisoning is a serious health concern that can have long-lasting effects on your well-being. Exposure to asbestos fibers can lead to various health issues, including lung cancer, mesothelioma, and asbestosis. If you suspect that you've been exposed to asbestos or are experiencing symptoms related to asbestos poisoning, it's crucial to take immediate action. 1. Recognize the Symptoms The first step in dealing with asbestos poisoning is to recognize the symptoms. Common signs of asbestos exposure include shortness of breath, persistent coughing, chest pain, and fatigue. Additionally, you may experience respiratory issues such as wheezing or difficulty breathing. Exploring the use of asbestos at Honeywell in Massachusetts can help you get a better understanding of the potential risks associated with asbestos exposure and the importance of taking proactive measures to protect yourself and your loved ones from its harmful effects. It's essential to pay attention to any changes in your health and seek medical attention if you suspect asbestos exposure.